← Leaderboards
Robert W Buchanan
University Of Maryland Baltimore
$22,479,930
Attributed
$24,033,656
Total exposure
18
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2005–24$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$28,727,669 · 19
By mechanism
P50$8,416,942 · 3
P30$8,050,748 · 3
R01$5,574,018 · 2
R24$2,435,186 · 1
R34$1,728,564 · 3
R33$1,216,723 · 1
Top collaborators
- William T. Carpenter6 shared
- Jordan Devylder3 shared
- Jason E Schiffman3 shared
- Anil K Malhotra1 shared
- Aristotle Nicholas Voineskos1 shared
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- Robert Schwarcz$12,978,861
- Gunvant K Thaker$11,810,209
- L. Elliot Hong$24,654,132
- Peter V Kochunov$14,596,957
- Ikwunga Wonodi$883,122
Others in their field
Top investigators on “Schizophrenia”
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$104,668,216
- Raquel E Gur · University Of Pennsylvania$60,189,770
- Mark J Daly · Broad Institute, Inc.$48,989,393
- John M Kane · Long Island Jewish Medical Center$45,235,871
- Carrie E Bearden · University Of California Los Angeles$42,025,230
- Scott W Woods · Yale University$41,221,536
Research focus
SchizophreniaImpaired CognitionDesignDouble-Blind MethodSymptomsImpairmentFunctional OutcomesBrainBehaviorPlacebosAttentionRandomizedAntipsychotic AgentsShort-Term MemoryPerformanceReportingCognitionAdverse EffectsParticipantMarylandReceptorProductionInterestCognitive Function
Grant awards (65)
Prebiotic Treatment in People with Schizophrenia$378,213
R33 · FY2024 · AT · contact PI
Prebiotic Treatment in People with Schizophrenia$35,701
R33 · FY2024 · AT · contact PI
Prebiotic Treatment in People with Schizophrenia$30,943
R33 · FY2024 · AT · contact PI
The Effects of Kynurenine Aminotransferase Inhibition in People with Schizophrenia$1,082,466
P50 · FY2023 · MH · contact PI
Prebiotic Treatment in People with Schizophrenia$385,933
R33 · FY2023 · AT · contact PI
The Effects of Kynurenine Aminotransferase Inhibition in People with Schizophrenia$603,309
P50 · FY2022 · MH · contact PI
Prebiotic Treatment in People with Schizophrenia$385,933
R33 · FY2022 · AT · contact PI
Neuromodulation of Social Cognitive Circuitry in People with Schizophrenia Spectrum Disorders$368,514
R61 · FY2022 · MH
The Effects of Kynurenine Aminotransferase Inhibition in People with Schizophrenia$603,309
P50 · FY2021 · MH · contact PI
Prebiotic Treatment in People with Schizophrenia$167,544
R61 · FY2021 · AT · contact PI
The Effects of Kynurenine Aminotransferase Inhibition in People with Schizophrenia$603,309
P50 · FY2020 · MH · contact PI
The Effects of Kynurenine Aminotransferase Inhibition in People with Schizophrenia$636,177
P50 · FY2019 · MH · contact PI
Prebiotic Treatment in People with Schizophrenia$308,878
R61 · FY2019 · AT · contact PI
Social Work Training to Reduce Duration of Untreated Psychosis$183,348
R34 · FY2019 · MH · contact PI
Kynurenic Acid in Schizophrenia: A Tryptophan Challenge Study$517,605
P50 · FY2018 · MH · contact PI
Prebiotic Treatment in People with Schizophrenia$308,878
R61 · FY2018 · AT · contact PI
3/3-Social Processes Initiative in Neurobiology of the Schizophrenia(s)$268,625
R01 · FY2018 · MH · contact PI
Social Work Training to Reduce Duration of Untreated Psychosis$222,251
R34 · FY2018 · MH · contact PI
Kynurenic Acid in Schizophrenia: A Tryptophan Challenge Study$432,382
P50 · FY2017 · MH · contact PI
3/3-Social Processes Initiative in Neurobiology of the Schizophrenia(s)$345,375
R01 · FY2017 · MH · contact PI
Social Work Training to Reduce Duration of Untreated Psychosis$275,335
R34 · FY2017 · MH · contact PI
Kynurenic Acid in Schizophrenia: A Tryptophan Challenge Study$480,608
P50 · FY2016 · MH · contact PI
3/3-Social Processes Initiative in Neurobiology of the Schizophrenia(s)$345,375
R01 · FY2016 · MH · contact PI
Kynurenic Acid in Schizophrenia: A Tryptophan Challenge Study$480,426
P50 · FY2015 · MH · contact PI
3/3-Social Processes Initiative in Neurobiology of the Schizophrenia(s)$345,375
R01 · FY2015 · MH · contact PI
1/2-Combined Oxytocin and CBSST for Social Function in People with Schizophrenia$191,875
R34 · FY2015 · MH · contact PI
3/3-Social Processes Initiative in Neurobiology of the Schizophrenia(s)$58,063
R01 · FY2015 · MH · contact PI
Kynurenic Acid in Schizophrenia: A Tryptophan Challenge Study$480,426
P50 · FY2014 · MH · contact PI
3/3-Social Processes Initiative in Neurobiology of the Schizophrenia(s)$345,375
R01 · FY2014 · MH · contact PI
1/2-Combined Oxytocin and CBSST for Social Function in People with Schizophrenia$307,000
R34 · FY2014 · MH · contact PI
1/2-Combined Oxytocin and CBSST for Social Function in People with Schizophrenia$191,875
R34 · FY2013 · MH · contact PI
ACISIR: Enhancing Recovery of People with Schizophrenia$481,818
R24 · FY2012 · MH · contact PI
Tretment of negative symptoms and cognitive impairment in schizoprenia$460,129
P50 · FY2012 · MH · contact PI
ACISIR: Enhancing Recovery of People with Schizophrenia$481,882
R24 · FY2011 · MH · contact PI
Tretment of negative symptoms and cognitive impairment in schizoprenia$463,386
P50 · FY2011 · MH · contact PI
Tretment of negative symptoms and cognitive impairment in schizoprenia$501,930
P50 · FY2010 · MH · contact PI
ACISIR: Enhancing Recovery of People with Schizophrenia$486,894
R24 · FY2010 · MH · contact PI
Tretment of negative symptoms and cognitive impairment in schizoprenia$527,061
P50 · FY2009 · MH · contact PI
ACISIR: Enhancing Recovery of People with Schizophrenia$494,462
R24 · FY2009 · MH · contact PI
CLINICAL TRIAL: ADJUNCTIVE RISPERIDONE IN CLOZAPINE TREATED PATIENTS$34,662
M01 · FY2009 · RR · contact PI
Tretment of negative symptoms and cognitive impairment in schizoprenia$544,419
P50 · FY2008 · MH · contact PI
ACISIR: Enhancing Recovery of People with Schizophrenia$490,130
R24 · FY2008 · MH · contact PI
The Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Weight...$129,774
R34 · FY2008 · MH · contact PI
CLINICAL TRIAL: ADJUNCTIVE RISPERIDONE IN CLOZAPINE TREATED PATIENTS$35,574
M01 · FY2008 · RR · contact PI
Advanced Centers for Interventions and Services Research$1,521,246
P30 · FY2007 · MH · contact PI
CORE--RESEARCH NETWORK DEVELOPMENT CORE$515,869
P30 · FY2007 · MH · contact PI
The Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Weight...$227,106
R34 · FY2007 · MH · contact PI
ADJUNCTIVE RISPERIDONE IN CLOZAPINE TREATED PATIENTS$40,664
M01 · FY2007 · RR · contact PI
Advanced Centers for Interventions and Services Research$1,567,585
P30 · FY2006 · MH · contact PI
Clozapine Treatment of Schizophrenic Patients$627,992
R01 · FY2006 · MH · contact PI
CORE--RESEARCH NETWORK DEVELOPMENT CORE$534,380
P30 · FY2006 · MH · contact PI
ADJUNCTIVE RISPERIDONE IN CLOZAPINE TREATED PATIENTS$40,774
M01 · FY2006 · RR · contact PI
Advanced Centers for Interventions and Services Research$1,605,182
P30 · FY2005 · MH
Clozapine Treatment of Schizophrenic Patients$733,724
R01 · FY2005 · MH
CORE--RESEARCH NETWORK DEVELOPMENT CORE$534,380
P30 · FY2005 · MH
Clozapine Treatment of Schizophrenic Patients$778,184
R01 · FY2004 · MH
CORE--RESEARCH NETWORK DEVELOPMENT CORE$534,380
P30 · FY2004 · MH
Clozapine Treatment of Schizophrenic Patients$609,287
R01 · FY2003 · MH
CORE--RESEARCH NETWORK DEVELOPMENT CORE$534,380
P30 · FY2003 · MH
Clozapine Treatment of Schizophrenic Patients$66,803
R01 · FY2003 · MH
Clozapine Treatment of Schizophrenic Patients$579,339
R01 · FY2002 · MH
ASSESSMENT CORE$266,631
P30 · FY2002 · MH
ASSESSMENT CORE$266,631
P30 · FY2001 · MH
CLOZAPINE TREATMENT OF SCHIZOPHRENIC OUTPATIENTS$470,501
R01 · FY2000 · MH
ASSESSMENT CORE$170,084
P30 · FY2000 · MH